PIVOTAL EFFICACY STUDY OF INHIBITION OF GASTRIC ACID SECRETION BY PANTOPRAZOLE

泮托拉唑抑制胃酸分泌的关键功效研究

• 批准号: 6118462
• 负责人: JOSEPH R PISEGNA
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118462
• 关键词: Zollinger Ellison syndrome; antiulcer drug; benzimidazoles; clinical research; clinical trials; drug screening /evaluation; endocrine neoplasm; gastric acid; gastric juice inhibitor; gastrointestinal disorder chemotherapy; human subject; human therapy evaluation; intravenous administration; secretion; stomach surgery

The objective is to identify the regimens of intravenously(IV) administered pantoprazole that would decrease and maintain acid secretion at less than 10mEq/ hr in patients with Zollinger-Ellison syndrome (ZES) with or without multiple endocrine neoplasia-type I (MEN-I) syndrome who have not under- gone partial gastrectomy and at less than 5 mEq/hr in those patients with ZES with or without MEN-I who have undergone parital gastrectomy and to minor safety.

目的是确定泮托拉唑静脉（IV）给药方案，在未接受胃部分切除术的Zollinger-Ellison综合征（ZES）伴或不伴多发性内分泌肿瘤I型（MEN-I）综合征患者中，该方案可降低并维持酸分泌低于10 mEq/hr，在ZES伴或不伴MEN患者中，该方案可降低并维持酸分泌低于5 mEq/hr。我曾接受过部分胃切除术，以轻微的安全。